Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.

摘要: Hormone-responsive early breast cancer is a highly curable disease. In premenopausal women, tamoxifen (TAM) still the standard treatment. Nowadays, up to 10 years of TAM can be safely administered, especially in women who remain premenopausal. Patients are considered perimenopausal should initially treated like patients. Depending on their serum hormone levels, these patients switched an aromatase inhibitor (AI) therapy once estradiol (E2) and follicle-stimulating (FSH) levels prove established postmenopausal status. several sequences endocrine treatment available. The AI induced upfront or sequentially by switching from Tam vice versa. Extended therapy, adding 5 letrozole after TAM, has also been proven beneficial certain patient subgroups. Genotyping cytochromes such as CYP2D6 did not have any added value identifying at higher risk recurrence. Nevertheless, all side effects need given high consideration. New strategies developed overcome resistance tested clinical studies. co-administered drugs specific inhibitors mammalian target rapamycin (mTOR), Src, phosphatidylinositol 3-kinase (PI3K) do improve responsiveness metastatic disease will eventually introduced cancer.